Back

Remote monitoring in cardiac transthyretin amyloidosis (ATTR-CM); a digital patient centred heart failure intervention during the COVID-19 pandemic.

22 May 2023 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 2 Multidisciplinary Interventions HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Tamer Rezk

Richmond Research Institute, London (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Acute kidney failure after heart transplantation, Risk factors and clinical outcome
Doctor F. Welz (Berlin, DE)
Abstract Slides
Presentation thumbnail
Long-term transesophageal echocardiographic characterization of flow dynamics of the V-Wave Ventura Interatrial Shunt device in patients with advanced heart failure
Professor J. Bax (Leiden, NL)
Abstract Slides
Presentation thumbnail
The predictive role of absolute lymphocyte counts for fatal infection in heart transplantation recipients who received induction therapy
Doctor J. Oh (Seoul, KR)
Abstract Slides
Presentation thumbnail
Preoperative neutrophil-to-lymphocyte ratio as a predictor of primary graft dysfunction and prognosis after heart transplantation
Doctor C. Millan Rodriguez (Sevilla, Spain, ES)
Abstract Slides
Presentation thumbnail
Clinical relevance and outcome of routine endomyocardial biopsy to detect rejection after heart transplantation
Mr L. Kieviet (Utrecht, NL)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - treatment 2

The Event

Event poster

Heart Failure 2023

22 May 2023 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Assessing the effectiveness of remote monitoring in heart failure patients with cardiac amyloidosis through the Satelia Cardio program
14 June 2025
thumbnail
Congress Session
ACT FAST for ATTR-CM: early clues in heart failure to raise clinical suspicion
17 May 2025
thumbnail
Congress Presentation
Atrial fibrillation in wild type transthyretin cardiac amyloidosis: prevalence, incidence and outcomes
23 May 2022
thumbnail
Congress Presentation
Burden of transthyretin amyloid cardiomyopathy in treatment-naive patients by heart failure severity: results from a large, non-interventional, real-world study
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources